21 completed, 3 recruiting, 3 terminated, 1 active not recruiting. 12 Not applicable, 5 Phase 3, 4 Phase 2, 3 Phase 4, 1 Phase 1.
Follow High Cholesterol: new trials by email Literature Review of High Cholesterol trials Research Report on High Cholesterol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cobas® Lumira Collection of Venous and Capillary Blood Samples for the Research, Optimization and Calibration of New Diagnostic Devices Blood samples are obtained and pseudonymized, prior to use for the development, optimization and calibration of diagnostic tests - Blood Clots, Infection and Inflammatory Reaction | Not yet recruiting | LumiraDx UK Limited | 30000 | 2026-04-01 | 2026-01-30 | |
| Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RN5681 in Healthy Volunteers RN5681, Placebo control - High Cholesterol | Phase 1 | Recruiting | Ikaria Bioscience Pty Ltd | 60 | 2026-03-12 | 2026-04-03 |
| FELLAShip to Better Health FELLAship - High Blood Glucose, High Cholesterol | Not applicable | Recruiting | University of Alabama at Birmingham | 90 | 2026-01-01 | 2026-01-22 |
| Healthy Living Anson Study Nutrition Education and Food Delivery, Physical Activity Comparator - Obesity (Disorder), Diabetes Type 2 | Not applicable | Completed | University of North Carolina, Chapel Hill | 44 | 2025-09-24 | 2026-09-28 |
| Effect of Herring Oil Concentrate on LDL Cholesterol Concentration in Adults Herring oil concentrate, Control - High Cholesterol | Not applicable | Active not recruiting | University of Bergen | 80 | 2024-08-12 | 2025-10-02 |
| The Benefits of the Measureof Epicardial Adipose Tissue During Coronary Calcium Assessment of the Refine Cardiovascular Risk Assessment at Reunion Island. Epicardial adipose tissue measurement on the available tododensitometry used for coronary calcium scoring - High Cholesterol, Lipodystrophy, Familial Partial | Completed | Centre Hospitalier Universitaire de la Réunion | 126 | 2024-05-06 | 2025-07-31 | |
| Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies Combination Therapy, Monotherapy obicetrapib, Monotherapy ezetimibe - Dyslipidemias, Hypercholesterolemia | Phase 3 | Completed | NewAmsterdam Pharma | 407 | 2024-03-01 | 2025-10-08 |
| Project WHADE: A Partner-Based Physical Activity Program for Women Project WHADE: A Partner-Based Physical Activity Program for Women - Hypertension, Type 2 Diabetes | Not applicable | Completed | Rowan University | 62 | 2024-01-02 | 2025-04-04 |
| Complete Lifestyle Medicine Intervention Program Lifestyle Medicine - High Cholesterol, Diabetes | Recruiting | Northern Ontario School of Medicine | 8 | 2023-11-06 | 2024-01-08 | |
| BVA-200 vs BVA-100 Validation Study BVA-200 - Heart Failure, High Blood Pressure | Completed | Daxor Corporation | 62 | 2023-05-23 | 2024-01-29 | |
| Benchtop NMR Spectroscopy for Assessment of Clinical Human Pathologies (BRANCH-P STUDY) Diabetes, Chronic Kidney Diseases | Unknown | Willows Health | 2000 | 2023-01-01 | 2022-08-15 | |
| Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies. Obicetrapib, Placebo - Dyslipidemias, High Cholesterol | Phase 3 | Completed | NewAmsterdam Pharma | 354 | 2022-07-25 | 2025-06-11 |
| A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy. Obicetrapib, Placebo - Dyslipidemia, Hypercholesterolemia | Phase 2 | Completed | NewAmsterdam Pharma | 102 | 2022-06-27 | 2024-10-29 |
| Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy Obicetrapib, Ezetimibe 10mg, Obicetrapib placebo - Dyslipidemias, High Cholesterol | Phase 2 | Completed | NewAmsterdam Pharma | 119 | 2022-03-09 | 2024-07-03 |
| Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies Placebo, Obicetrapib - Dyslipidemias, High Cholesterol | Phase 3 | Completed | NewAmsterdam Pharma | 2530 | 2021-12-15 | 2025-09-19 |
| Technology-Assisted Cholesterol Trial in Consumers (TACTiC) 5 mg rosuvastatin calcium with a Web App (combination product) - High Cholesterol | Phase 3 | Completed | AstraZeneca | 1196 | 2021-07-08 | 2024-10-30 |
| Evolocumab In Advanced Chronic Kidney Disease Trial Evolocumab, Placebo - Chronic Kidney Diseases, High Cholesterol | Phase 4 | Withdrawn | NYU Langone Health | 2021-03-01 | 2022-07-28 | |
| Randomized Study of Obicetrapib in Combination With Ezetimibe Obicetrapib 5mg, Ezetimibe 10mg, Placebo - Dyslipidemias, High Cholesterol | Phase 2 | Completed | NewAmsterdam Pharma | 112 | 2021-02-23 | 2024-04-24 |
| Randomized Study of Obicetrapib as an Adjunct to Statin Therapy Obicetrapib - Dyslipidemias, High Cholesterol | Phase 2 | Completed | NewAmsterdam Pharma | 120 | 2021-02-18 | 2024-07-12 |
| Online Trial Examining Validity and Reliability of the Shared Decision Making Process Survey High Cholesterol, High Blood Pressure | Completed | Massachusetts General Hospital | 539 | 2020-03-17 | 2022-05-20 |
Showing 20 of 31. Sign in to see all of them.
Hypercholesterolemia (31) · Hypertension (10) · Diabetes Mellitus (9) · Dyslipidemias (7) · Obesity (7) · Heart Diseases (6) · Atherosclerosis (5) · Cardiovascular Diseases (4) · Diabetes Mellitus, Type 2 (3) · Hyperlipoproteinemia Type II (3) · Renal Insufficiency, Chronic (3) · Colorectal Neoplasms (2) · Depression (2) · Hyperglycemia (2) · Infections (2)
Nutritional and Metabolic Diseases (31) · Hyperlipidemias (30) · Lipid Metabolism Disorders (30) · Metabolic Diseases (30) · Dyslipidemias (24) · Vascular Diseases (17) · Cardiovascular Diseases (16) · Glucose Metabolism Disorders (13) · Endocrine System Diseases (12) · Pathological Conditions, Signs and Symptoms (12) · Body Weight (8) · Signs and Symptoms (8) · Nutrition Disorders (7) · Overnutrition (7) · Arterial Occlusive Diseases (6)
Ezetimibe (4) · Atorvastatin (2) · 1-octacosanol (1) · Art Therapy (1) · Cholesterol Ester Transfer Proteins (1) · Combined Modality Therapy (1) · Curcumin (1) · Decision Support Techniques (1) · Exercise (1) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1) · Hypolipidemic Agents (1) · Music Therapy (1) · Nutrition Assessment (1) · Pravastatin (1) · Rosuvastatin Calcium (1)
NewAmsterdam Pharma (7) · Massachusetts General Hospital (2) · AstraZeneca (1) · Centre Hospitalier Universitaire de la Réunion (1) · Daxor Corporation (1) · Duke University (1) · Gachon University Gil Medical Center (1) · Ikaria Bioscience Pty Ltd (1) · James Backes, PharmD (1) · Lisa Gallagher (1) · LumiraDx UK Limited (1) · Mayo Clinic (1) · NYU Langone Health (1) · Northern Ontario School of Medicine (1) · Ohio State University (1)
United States (20) · Netherlands (3) · Canada (2) · Czechia (2) · Georgia (2) · Japan (2) · Norway (2) · Poland (2) · United Kingdom (2) · Australia (1) · China (1) · Denmark (1) · Reunion (1) · South Africa (1) · South Korea (1)
Marc Ditmarsch (3) · Karen Sepucha, PhD (2) · Marc Ditmarsch, MD (2) · Anissa I Vines, MS, PhD (1) · Caroline Rheaume, MD (1) · Danielle Arigo, Ph.D. (1) · Darrell Gray, MD (1) · David Charytan, MD (1) · David Reboussin, PhD (1) · James M. Backes, PharmD (1) · Janus L Thomsen, MD, PhD (1) · Jonathan Feldschuh (1) · LaPrincess C Brewer, MD, MPH (1) · Lisa M Gallagher, MA (1) · Lynda Szczech, MD (1)
PMID 12485966, PMID 16818923, PMID 17384344, PMID 20860820, PMID 23113909, PMID 23863812, PMID 24040920, PMID 24279738, PMID 25527677, PMID 25559009, PMID 26499033, PMID 27548405, PMID 27807041, PMID 31430294, PMID 33200999, PMID 35861827, PMID 35953719, PMID 38195473, PMID 38375072, PMID 38599257, PMID 38705341, PMID 38726886, PMID 39128497, PMID 39641169, PMID 39740215, PMID 39886351, PMID 39968784, PMID 40337982, PMID 40347969, PMID 41021523, PMID 41109840, PMID 41190670, PMID 41349713, PMID 41760952, PMID 41823253, PMID 42087898, PMID 42102943, PMID 9018491
OT2HL158287 (1)